Skip to main content

Shortened LSD Intervention for Major Depressive Disorder

The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.

Status
planned
Phase
Phase 1
Institution
Johns Hopkins University
Principal investigator
Sandeep Nayak, MD
Start date
2026-08-31
End date
2027-12-01
Registry ID
NCT07503002

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.